HC Advisors’s BioNTech BNTX Stock Holding History

HC Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,072	Closed	-$332K	–	91
2020 Q4	$332K	Sell	4,072 -809	-17%	-$79.4K	0.23%	56
2020 Q3	$338K	Sell	4,881 -2,635	-35%	-$189K	0.27%	48
2020 Q2	$502K	Buy	+7,516	New	+$375K	0.42%	45

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

HC Advisors's BNTX Position: Q1 2021 in Review

HC Advisors sold out of BioNTech (BNTX) in Q1 2021, closing a stake of 4,072 shares — an estimated $332K sold.

HC Advisors first reported a position in BNTX in Q2 2020 and held it in 3 quarters. The position peaked at $502K in Q2 2020. 225 funds tracked by Wall St. Rank hold BNTX as of Q1 2021.

HC Advisors reported no remaining BioNTech position as of Q1 2021 after selling out during the quarter.
HC Advisors sold 4,072 BioNTech shares in Q1 2021, an estimated $332K.
HC Advisors first reported a position in BioNTech in Q2 2020 and held it in 3 quarters.
HC Advisors's BioNTech position peaked at $502K in Q2 2020.
225 funds tracked by Wall St. Rank held BioNTech as of Q1 2021.

Based on HC Advisors's 13F filing for Q1 2021, filed 7 May 2021.